Intrinsic value of VIVUS - VVUS

Previous Close

$0.46

  Intrinsic Value

$0.04

stock screener

  Rating & Target

str. sell

-91%

Previous close

$0.46

 
Intrinsic value

$0.04

 
Up/down potential

-91%

 
Rating

str. sell

We calculate the intrinsic value of VVUS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  30.53
  15.40
  14.36
  13.42
  12.58
  11.82
  11.14
  10.53
  9.97
  9.48
  9.03
  8.63
  8.26
  7.94
  7.64
  7.38
  7.14
  6.93
  6.73
  6.56
  6.40
  6.26
  6.14
  6.02
  5.92
  5.83
  5.75
  5.67
  5.60
  5.54
  5.49
Revenue, $m
  124
  143
  164
  186
  209
  234
  260
  287
  316
  346
  377
  409
  443
  478
  515
  553
  592
  633
  676
  720
  766
  815
  865
  917
  971
  1,027
  1,087
  1,148
  1,212
  1,280
  1,350
Variable operating expenses, $m
 
  235
  269
  305
  344
  384
  427
  472
  519
  568
  620
  673
  729
  787
  847
  909
  974
  1,042
  1,112
  1,185
  1,261
  1,340
  1,422
  1,508
  1,597
  1,690
  1,787
  1,889
  1,995
  2,105
  2,221
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  69
  235
  269
  305
  344
  384
  427
  472
  519
  568
  620
  673
  729
  787
  847
  909
  974
  1,042
  1,112
  1,185
  1,261
  1,340
  1,422
  1,508
  1,597
  1,690
  1,787
  1,889
  1,995
  2,105
  2,221
Operating income, $m
  56
  -92
  -106
  -120
  -135
  -151
  -168
  -185
  -204
  -223
  -243
  -264
  -286
  -308
  -332
  -357
  -382
  -409
  -436
  -465
  -494
  -525
  -558
  -591
  -626
  -663
  -701
  -741
  -782
  -825
  -871
EBITDA, $m
  57
  -92
  -105
  -119
  -134
  -150
  -167
  -185
  -203
  -222
  -242
  -263
  -285
  -308
  -331
  -356
  -381
  -408
  -435
  -463
  -493
  -524
  -556
  -590
  -625
  -661
  -699
  -739
  -780
  -823
  -869
Interest expense (income), $m
  15
  15
  -1
  0
  0
  0
  1
  1
  2
  2
  3
  3
  4
  4
  5
  6
  6
  7
  8
  8
  9
  10
  11
  11
  12
  13
  14
  15
  16
  17
  18
Earnings before tax, $m
  23
  -107
  -105
  -119
  -135
  -151
  -168
  -186
  -205
  -225
  -246
  -267
  -290
  -313
  -337
  -362
  -388
  -415
  -444
  -473
  -503
  -535
  -568
  -603
  -639
  -676
  -715
  -756
  -798
  -843
  -889
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  23
  -107
  -105
  -119
  -135
  -151
  -168
  -186
  -205
  -225
  -246
  -267
  -290
  -313
  -337
  -362
  -388
  -415
  -444
  -473
  -503
  -535
  -568
  -603
  -639
  -676
  -715
  -756
  -798
  -843
  -889

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  270
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  306
  42
  48
  54
  61
  68
  75
  83
  92
  100
  109
  119
  129
  139
  149
  161
  172
  184
  196
  209
  223
  237
  251
  266
  282
  298
  315
  333
  352
  372
  392
Adjusted assets (=assets-cash), $m
  36
  42
  48
  54
  61
  68
  75
  83
  92
  100
  109
  119
  129
  139
  149
  161
  172
  184
  196
  209
  223
  237
  251
  266
  282
  298
  315
  333
  352
  372
  392
Revenue / Adjusted assets
  3.444
  3.405
  3.417
  3.444
  3.426
  3.441
  3.467
  3.458
  3.435
  3.460
  3.459
  3.437
  3.434
  3.439
  3.456
  3.435
  3.442
  3.440
  3.449
  3.445
  3.435
  3.439
  3.446
  3.447
  3.443
  3.446
  3.451
  3.447
  3.443
  3.441
  3.444
Average production assets, $m
  1
  1
  1
  1
  2
  2
  2
  2
  3
  3
  3
  3
  4
  4
  4
  4
  5
  5
  5
  6
  6
  7
  7
  7
  8
  8
  9
  9
  10
  10
  11
Working capital, $m
  255
  -7
  -8
  -9
  -10
  -11
  -12
  -14
  -15
  -17
  -18
  -20
  -21
  -23
  -25
  -27
  -28
  -30
  -32
  -35
  -37
  -39
  -41
  -44
  -47
  -49
  -52
  -55
  -58
  -61
  -65
Total debt, $m
  241
  -10
  -4
  2
  8
  14
  21
  28
  35
  43
  51
  60
  69
  78
  88
  97
  108
  119
  130
  141
  153
  166
  179
  193
  207
  222
  237
  253
  270
  287
  306
Total liabilities, $m
  288
  37
  43
  49
  55
  61
  68
  75
  82
  90
  98
  107
  116
  125
  135
  144
  155
  166
  177
  188
  200
  213
  226
  240
  254
  269
  284
  300
  317
  334
  353
Total equity, $m
  18
  4
  5
  5
  6
  7
  8
  8
  9
  10
  11
  12
  13
  14
  15
  16
  17
  18
  20
  21
  22
  24
  25
  27
  28
  30
  32
  33
  35
  37
  39
Total liabilities and equity, $m
  306
  41
  48
  54
  61
  68
  76
  83
  91
  100
  109
  119
  129
  139
  150
  160
  172
  184
  197
  209
  222
  237
  251
  267
  282
  299
  316
  333
  352
  371
  392
Debt-to-equity ratio
  13.389
  -2.310
  -0.890
  0.280
  1.250
  2.070
  2.770
  3.360
  3.870
  4.320
  4.700
  5.050
  5.350
  5.620
  5.860
  6.070
  6.270
  6.440
  6.610
  6.750
  6.890
  7.010
  7.130
  7.230
  7.330
  7.420
  7.510
  7.590
  7.660
  7.740
  7.800
Adjusted equity ratio
  -7.000
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  23
  -107
  -105
  -119
  -135
  -151
  -168
  -186
  -205
  -225
  -246
  -267
  -290
  -313
  -337
  -362
  -388
  -415
  -444
  -473
  -503
  -535
  -568
  -603
  -639
  -676
  -715
  -756
  -798
  -843
  -889
Depreciation, amort., depletion, $m
  1
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
Funds from operations, $m
  30
  -107
  -105
  -119
  -135
  -151
  -168
  -186
  -205
  -225
  -245
  -267
  -289
  -312
  -336
  -361
  -387
  -414
  -443
  -472
  -502
  -534
  -567
  -601
  -637
  -674
  -713
  -754
  -796
  -841
  -887
Change in working capital, $m
  -8
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
Cash from operations, $m
  38
  -106
  -104
  -118
  -133
  -150
  -167
  -185
  -204
  -223
  -244
  -265
  -287
  -310
  -334
  -359
  -385
  -412
  -440
  -470
  -500
  -532
  -564
  -599
  -634
  -672
  -710
  -751
  -793
  -837
  -884
Maintenance CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
New CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
Cash from investing activities, $m
  -40
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -3
  -3
  -3
Free cash flow, $m
  -2
  -106
  -104
  -119
  -134
  -150
  -167
  -185
  -204
  -224
  -245
  -266
  -288
  -311
  -336
  -361
  -387
  -414
  -442
  -471
  -502
  -533
  -566
  -600
  -636
  -674
  -713
  -753
  -796
  -840
  -886
Issuance/(repayment) of debt, $m
  -9
  -242
  5
  6
  6
  6
  7
  7
  7
  8
  8
  8
  9
  9
  10
  10
  10
  11
  11
  12
  12
  13
  13
  14
  14
  15
  15
  16
  17
  18
  18
Issuance/(repurchase) of shares, $m
  0
  354
  106
  120
  136
  152
  169
  187
  206
  226
  247
  268
  291
  314
  338
  363
  389
  417
  445
  474
  505
  537
  570
  604
  640
  678
  717
  758
  800
  845
  891
Cash from financing (excl. dividends), $m  
  -9
  112
  111
  126
  142
  158
  176
  194
  213
  234
  255
  276
  300
  323
  348
  373
  399
  428
  456
  486
  517
  550
  583
  618
  654
  693
  732
  774
  817
  863
  909
Total cash flow (excl. dividends), $m
  -11
  6
  7
  7
  8
  8
  9
  9
  10
  10
  10
  11
  11
  12
  12
  13
  13
  14
  14
  15
  15
  16
  17
  17
  18
  19
  20
  20
  21
  22
  23
Retained Cash Flow (-), $m
  -25
  -354
  -106
  -120
  -136
  -152
  -169
  -187
  -206
  -226
  -247
  -268
  -291
  -314
  -338
  -363
  -389
  -417
  -445
  -474
  -505
  -537
  -570
  -604
  -640
  -678
  -717
  -758
  -800
  -845
  -891
Prev. year cash balance distribution, $m
 
  261
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -87
  -99
  -113
  -128
  -144
  -161
  -178
  -197
  -216
  -236
  -257
  -279
  -302
  -326
  -351
  -376
  -403
  -431
  -459
  -489
  -521
  -553
  -587
  -622
  -659
  -697
  -737
  -779
  -822
  -868
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  -83
  -90
  -98
  -105
  -111
  -116
  -120
  -123
  -124
  -124
  -122
  -119
  -115
  -109
  -103
  -96
  -88
  -79
  -71
  -62
  -54
  -46
  -38
  -32
  -26
  -20
  -16
  -12
  -9
  -7
Current shareholders' claim on cash, %
  100
  50.0
  4.9
  0.5
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

FINANCIAL RATIOS  of  VIVUS (VVUS)

Valuation Ratios
P/E Ratio 2.1
Price to Sales 0.4
Price to Book 2.7
Price to Tangible Book
Price to Cash Flow 1.3
Price to Free Cash Flow 1.3
Growth Rates
Sales Growth Rate 30.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate -100%
Financial Strength
Quick Ratio 30
Current Ratio 0
LT Debt to Equity 1288.9%
Total Debt to Equity 1338.9%
Interest Coverage 3
Management Effectiveness
Return On Assets 13%
Ret/ On Assets - 3 Yr. Avg. -8.6%
Return On Total Capital 9.5%
Ret/ On T. Cap. - 3 Yr. Avg. -16.6%
Return On Equity 418.2%
Return On Equity - 3 Yr. Avg. 34.4%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 91.9%
Gross Margin - 3 Yr. Avg. 75.7%
EBITDA Margin 31.5%
EBITDA Margin - 3 Yr. Avg. -33.3%
Operating Margin 44.4%
Oper. Margin - 3 Yr. Avg. -21.5%
Pre-Tax Margin 18.5%
Pre-Tax Margin - 3 Yr. Avg. -50.7%
Net Profit Margin 18.5%
Net Profit Margin - 3 Yr. Avg. -50.7%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

VVUS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the VVUS stock intrinsic value calculation we used $124 million for the last fiscal year's total revenue generated by VIVUS. The default revenue input number comes from 2016 income statement of VIVUS. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our VVUS stock valuation model: a) initial revenue growth rate of 15.4% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for VVUS is calculated based on our internal credit rating of VIVUS, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of VIVUS.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of VVUS stock the variable cost ratio is equal to 164.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for VVUS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 6.4% for VIVUS.

Corporate tax rate of 27% is the nominal tax rate for VIVUS. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the VVUS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for VVUS are equal to 0.8%.

Life of production assets of 1 years is the average useful life of capital assets used in VIVUS operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for VVUS is equal to -4.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $18 million for VIVUS - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 108.628 million for VIVUS is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of VIVUS at the current share price and the inputted number of shares is $0.0 billion.

RELATED COMPANIES Price Int.Val. Rating
OREX Orexigen Thera 0.830 1.00  sell
ARNA Arena Pharmace 40.80 0.25  str.sell
SNY Sanofi ADR 39.91 40.06  hold
CAH Cardinal Healt 69.34 123.25  str.buy
PFE Pfizer 36.26 28.29  sell
LLY Eli Lilly 78.97 111.38  buy

COMPANY NEWS

▶ VIVUS Announces Change in Leadership   [Dec-26-17 04:05PM  Marketwired]
▶ ETFs with exposure to VIVUS, Inc. : December 22, 2017   [Dec-22-17 11:51AM  Capital Cube]
▶ ETFs with exposure to VIVUS, Inc. : December 11, 2017   [Dec-11-17 02:15PM  Capital Cube]
▶ ETFs with exposure to VIVUS, Inc. : December 1, 2017   [Dec-01-17 10:49AM  Capital Cube]
▶ ETFs with exposure to VIVUS, Inc. : November 20, 2017   [Nov-20-17 01:34PM  Capital Cube]
▶ ETFs with exposure to VIVUS, Inc. : November 10, 2017   [Nov-10-17 12:55PM  Capital Cube]
▶ Vivus reports 3Q loss   [Nov-07-17 04:57PM  Associated Press]
▶ VIVUS, Inc. to Host Earnings Call   [10:40AM  ACCESSWIRE]
▶ VIVUS Completes Tacrolimus Pre-IND Meeting With FDA   [Nov-02-17 07:00AM  Marketwired]
▶ ETFs with exposure to VIVUS, Inc. : October 30, 2017   [Oct-30-17 12:22PM  Capital Cube]
▶ ETFs with exposure to VIVUS, Inc. : October 20, 2017   [Oct-20-17 10:28AM  Capital Cube]
▶ ETFs with exposure to VIVUS, Inc. : October 9, 2017   [Oct-09-17 12:11PM  Capital Cube]
▶ VIVUS Reports Second Quarter 2017 Financial Results   [Aug-03-17 04:15PM  Marketwired]
Financial statements of VVUS
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.